More News! 10 Nov 2022 Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) […] November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Replay Bio launches HSV gene therapy company to target retinal eye disease Replay Bio has announced the launch of Eudora, an HSV (herpes simplex virus) gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Eudora’s co-founders Joe Glorioso, Mark Blumenkranz, David Schaffer, and Vinit Mahajan, are entrepreneurs who have worked in […] October 31, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2022 Syncona to acquire Applied Genetic Technologies Corporation Healthcare company Syncona Limited says its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation (AGTC). AGTC is a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an […] October 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2022 Protocol for treatment of neurotrophic keratopathy submitted to FDA by ReGenTree Protocol for a second phase 3 clinical trial for a treatment for neurotrophic keratopathy (NK) – a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, has been submitted. RegeneRx Biopharmaceuticals reported that its U.S. joint venture partner and licensee, HLB Therapeutics, together called ReGenTree, made the submission to the U.S. Food and […] September 27, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 SparingVision raises €75M for genomic medicines for ocular diseases SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, has raised €75 million ($75 million) in series B financing. The round was co-led by Jeito Capital and UPMC Enterprises, with additional participation from 4BIO Capital, Bpifrance, the RD fund, venture arm of Foundation Fighting Blindness, and Ysios Capital. Proceeds from the financing will […] September 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Sep 2022 Improved vision with less eye injections for patients after primary endpoints met in trials The primary endpoints in two clinical trials investigating drug aflibercept 8 mg with 12 and 16-week dosing regimes, for patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), have been met. The trials, called PHOTON in DME and PULSAR in wAMD, both showed the dosing regimens achieved non-inferiority in vision gains compared […] September 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Marketing authorization granted for treatment of serious retinal diseases The European Commission has granted marketing authorization to Ranivisio, a treatment for several serious retinal diseases. Polpharma Biologics Group BV, Formycon AG and their Swiss joint venture, Bioeq AG, announced the news today (August 29) that the authorization was granted to Ranivisio, which is a biosimilar to Lucentis, a ranibizumab injection. Positive opinion: CHMP The […] August 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 New drug application for treatment of dry eyes disease submitted to FDA A treatment for dry eye symptoms associated with Meibomian gland dysfunction (MGD) has been submitted under a New Drug Application (NDA) and will be considered by the US Food and Drug Administration. The application was submitted at the end of last month (June) by the Canada-based global eye health company, Bausch and Lomb Corporation, and […] July 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 BRIM Biotechnology enters OTC trading in Taiwan BRIM Biotechnology, Inc.has entered OTC (over the counter) trading in Taiwan. Established in July 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. The company’s current paid-in capital is approximately $23 million. BRIM has several novel drug products in its pipeline, all underpinned by […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 Sling Therapeutics emerges with $35M to tackle thyroid eye disease Michigan-based biopharma company Sling Therapeutics, Inc. has launched, with $35 million in series A financing led by TPG’s The Rise Fund. The company is focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The funds support a phase 2b clinical trial evaluating its investigational drug, linsitinib. “We […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2022 Europe’s Ophthalmology Scene Stays Hot for Biotech Funding Ophthalmology-focused startups had a record year for venture capital funding in 2021. Impressive Series A rounds and collaborations hint at a continuing upward trend for the field in 2022. Biotech companies researching treatments for ophthalmological conditions experienced a splurge of venture capital (VC) funding in 2021, with the total more than trebling the haul from […] March 3, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2020 Phase II Success for Once-a-Day Eye Drops after Cataract Surgery A nanoparticle steroid therapy developed by Swiss biotech Oculis has reduced eye pain and inflammation in a phase II trial in cataract surgery patients. This is the second positive phase II this year for the company, which closed a €31M Series B fundraising round at the beginning of 2019. In February this year, Oculis also […] May 20, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email